{"id":1118600,"date":"2023-10-16T06:42:05","date_gmt":"2023-10-16T10:42:05","guid":{"rendered":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/uncategorized\/the-role-and-impact-of-alternative-polyadenylation-and-mirna-nature-com\/"},"modified":"2023-10-16T06:42:05","modified_gmt":"2023-10-16T10:42:05","slug":"the-role-and-impact-of-alternative-polyadenylation-and-mirna-nature-com","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/transhuman-news-blog\/human-genetics\/the-role-and-impact-of-alternative-polyadenylation-and-mirna-nature-com\/","title":{"rendered":"The role and impact of alternative polyadenylation and miRNA … – Nature.com"},"content":{"rendered":"

Domcke, S. et al. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013). <\/p>\n

Article ADS PubMed Google Scholar <\/p>\n

Kbel, M. et al. Ovarian carcinoma subtypes are different diseases: Implications for biomarker studies. PLoS Med. 5(12), e232 (2008). <\/p>\n

Article PubMed PubMed Central Google Scholar <\/p>\n

Soslow, R. A. Histologic subtypes of ovarian carcinoma: An overview. Int. J. Gynecol. Pathol. 27(2), 161172 (2008). <\/p>\n

PubMed Google Scholar <\/p>\n

Ip, C. K. M. et al. Stemness and chemoresistance in epithelial ovarian carcinoma cells under shear stress. Sci. Rep. 6, 26788 (2016). <\/p>\n

Article ADS CAS PubMed PubMed Central Google Scholar <\/p>\n

Galluzzi, L. et al. Systems biology of cisplatin resistance: Past, present and future. Cell Death Dis. 5(5), e1257e1257 (2014). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Seborova, K. et al. Association of ABC gene profiles with time to progression and resistance in ovarian cancer revealed by bioinformatics analyses. Cancer Med. 8(2), 606616 (2019). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Sharom, F. J. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9(1), 105127 (2008). <\/p>\n

Article CAS PubMed Google Scholar <\/p>\n

Smida, M. & Nijman, S. Functional drug-gene interactions in lung cancer. Expert Rev. Mol. Diagn. 12(3), 291302 (2012). <\/p>\n

Article CAS PubMed Google Scholar <\/p>\n

Shanker, S. et al. Drug resistance in lung cancer. Lung Cancer: Targets Ther. 1, 2336 (2010). <\/p>\n

CAS Google Scholar <\/p>\n

Chung, F. S. et al. Disrupting P-glycoprotein function in clinical settings: What can we learn from the fundamental aspects of this transporter?. Am. J. Cancer Res. 6(8), 15831598 (2016). <\/p>\n

CAS PubMed PubMed Central Google Scholar <\/p>\n

Derti, A. et al. A quantitative atlas of polyadenylation in five mammals. Genome Res. 22(6), 11731183 (2012). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Shi, Y. Alternative polyadenylation: New insights from global analyses. RNA 18(12), 21052117 (2012). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Reyes, A. & Huber, W. Alternative start and termination sites of transcription drive most transcript isoform differences across human tissues. Nucleic Acids Res. 46(2), 582592 (2017). <\/p>\n

Article PubMed Central Google Scholar <\/p>\n

Mandel, C., Bai, Y. & Tong, L. Protein factors in pre-mRNA 3-end processing. Cell. Mol. Life Sci. 65(78), 10991122 (2008). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Danckwardt, S., Hentze, M. W. & Kulozik, A. E. 3 end mRNA processing: Molecular mechanisms and implications for health and disease. EMBO J. 27(3), 482498 (2008). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Neilson, J. R. & Sandberg, R. Heterogeneity in mammalian RNA 3 end formation. Exp. Cell Res. 316(8), 13571364 (2010). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Chekulaeva, M., Hentze, M. W. & Ephrussi, A. Bruno acts as a dual repressor of oskar translation, promoting mRNA oligomerization and formation of silencing particles. Cell 124(3), 521533 (2006). <\/p>\n

Article CAS PubMed Google Scholar <\/p>\n

Berkovits, B. D. & Mayr, C. Alternative 3 UTRs act as scaffolds to regulate membrane protein localization. Nature 522(7556), 363367 (2015). <\/p>\n

Article ADS CAS PubMed PubMed Central Google Scholar <\/p>\n

An, J. J. et al. Distinct role of long 3 UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. Cell 134(1), 175187 (2008). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Gruber, A. R. et al. Global 3 UTR shortening has a limited effect on protein abundance in proliferating T cells. Nat. Commun. 5, 5465 (2014). <\/p>\n

Article ADS CAS PubMed Google Scholar <\/p>\n

Magee, P., Shi, L. & Garofalo, M. Role of microRNAs in chemoresistance. Ann. Transl. Med. 3(21), 332 (2015). <\/p>\n

PubMed PubMed Central Google Scholar <\/p>\n

Tanaka, I. Regulation of alternative splicing and polyadenylation by genotoxic anti-cancer agents. Universit Paris-Saclay (2019). <\/p>\n

Cole, S. P. C. Targeting multidrug resistance protein 1 (MRP1, ABCC1): Past, present, and future. Annu. Rev. Pharmacol. Toxicol. 54(1), 95117 (2014). <\/p>\n

Article CAS PubMed Google Scholar <\/p>\n

Hipfner, D. R. et al. Monoclonal antibodies that inhibit the transport function of the 190-kDa multidrug resistance protein, MRP. Localization of their epitopes to the nucleotide-binding domains of the protein. J. Biol. Chem. 274(22), 1542015426 (1999). <\/p>\n

Article CAS PubMed Google Scholar <\/p>\n

Emmanouilidi, A. et al. Inhibition of the lysophosphatidylinositol transporter ABCC1 reduces prostate cancer cell growth and sensitizes to chemotherapy. Cancers (Basel) 12(8), 2022 (2020). <\/p>\n

Article CAS PubMed Google Scholar <\/p>\n

Fanelli, M. et al. Targeting ABCB1 and ABCC1 with their specific inhibitor CBT-1 can overcome drug resistance in osteosarcoma. Curr. Cancer Drug Targets 16(3), 261274 (2016). <\/p>\n

Article MathSciNet CAS PubMed Google Scholar <\/p>\n

Stefan, S. M. Multi-target ABC transporter modulators: What next and where to go?. Future Med. Chem. 11(18), 23532358 (2019). <\/p>\n

Article CAS PubMed Google Scholar <\/p>\n

Schumacher, T. et al. ABC transporters B1, C1 and G2 differentially regulate neuroregeneration in mice. PLOS ONE 7(4), e35613 (2012). <\/p>\n

Article ADS CAS PubMed PubMed Central Google Scholar <\/p>\n

Galluzzi, L. et al. Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25(3), 486541 (2018). <\/p>\n

Article PubMed PubMed Central Google Scholar <\/p>\n

Basuli, D. et al. Iron addiction: A novel therapeutic target in ovarian cancer. Oncogene 36(29), 40894099 (2017). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Li, D., Zhang, M. & Chao, H. Significance of glutathione peroxidase 4 and intracellular iron level in ovarian cancer cellsutilization of ferroptosis mechanism. Inflamm. Res. 70(10), 11771189 (2021). <\/p>\n

Article CAS PubMed Google Scholar <\/p>\n

Chen, L. et al. Erastin sensitizes glioblastoma cells to temozolomide by restraining xCT and cystathionine--lyase function. Oncol. Rep. 33(3), 14651474 (2015). <\/p>\n

Article MathSciNet CAS PubMed Google Scholar <\/p>\n

Yamaguchi, H. et al. Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells. Clin. Cancer Res: Off. J. Am. Assoc. Cancer Res. 19(4), 845854 (2013). <\/p>\n

Article CAS Google Scholar <\/p>\n

Zhou, H.-H. et al. Erastin reverses ABCB1-mediated docetaxel resistance in ovarian cancer. Front. Oncol. 9, 13981398 (2019). <\/p>\n

Article PubMed PubMed Central Google Scholar <\/p>\n

Beaufort, C. M. et al. Ovarian cancer cell line panel (OCCP): Clinical importance of in vitro morphological subtypes. PLOS ONE 9(9), e103988 (2014). <\/p>\n

Article ADS PubMed PubMed Central Google Scholar <\/p>\n

Perets, R. et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer cell 24(6), 751765 (2013). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Klotz, D. M. & Wimberger, P. Cells of origin of ovarian cancer: Ovarian surface epithelium or fallopian tube?. Arch. Gynecol. Obstet. 296(6), 10551062 (2017). <\/p>\n

Article PubMed Google Scholar <\/p>\n

Soong, T. R. et al. The fallopian tube, precursor escape and narrowing the knowledge gap to the origins of high-grade serous carcinoma. Gynecol. Oncol. 152(2), 426433 (2019). <\/p>\n

Article PubMed Google Scholar <\/p>\n

Ducie, J. et al. Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat. Commun. 8(1), 990 (2017). <\/p>\n

Article ADS PubMed PubMed Central Google Scholar <\/p>\n

Masamha, C. P. & Todd, Z. Adapting 3 rapid amplification of CDNA ends to map transcripts in cancer. J. Vis. Exp. 133, e57318 (2018). <\/p>\n

Google Scholar <\/p>\n

Bruhn, O. et al. Alternative polyadenylation of ABC-transporters of the C-family (ABCC1, ABCC2, ABCC3) and implications on post-transcriptional micro-RNA regulation. Mol. Pharmacol. 97, 112122 (2019). <\/p>\n

Article PubMed Google Scholar <\/p>\n

Kurnit, K. C., Fleming, G. F. & Lengyel, E. Updates and new options in advanced epithelial ovarian cancer treatment. Obstet. Gynecol. 137(1), 108 (2021). <\/p>\n

Article CAS PubMed Google Scholar <\/p>\n

Gao, B. et al. Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Sci. Rep. 4, 4669 (2014). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Mayr, C. Regulation by 3-untranslated regions. Annu. Rev. Genetics 51(1), 171194 (2017). <\/p>\n

Article CAS Google Scholar <\/p>\n

Friedman, R. C. et al. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 19(1), 92105 (2009). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Mayr, C. & Bartel, D. P. Widespread shortening of 3UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 138(4), 673684 (2009). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Masamha, C. P. et al. CFIm25 links alternative polyadenylation to glioblastoma tumour suppression. Nature 510(7505), 412416 (2014). <\/p>\n

Article ADS CAS PubMed PubMed Central Google Scholar <\/p>\n

He, X.-J. et al. Aberrant alternative polyadenylation is responsible for survivin up-regulation in ovarian cancer. Chin. Med. J. 129(10), 11401146 (2016). <\/p>\n

Article CAS PubMed PubMed Central Google Scholar <\/p>\n

Patch, A.-M. et al. Wholegenome characterization of chemoresistant ovarian cancer. Nature 521(7553), 489494 (2015). <\/p>\n

Article ADS CAS PubMed Google Scholar <\/p>\n

Chen, M. et al. miR-133b down-regulates ABCC1 and enhances the sensitivity of CRC to anti-tumor drugs. Oncotarget 8(32), 5298352994 (2017). <\/p>\n

Article PubMed PubMed Central Google Scholar <\/p>\n

Ma, J. et al. Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of ABCC1. J. Drug Target 23(6), 519524 (2015). <\/p>\n

<\/p>\n

More:
\nThe role and impact of alternative polyadenylation and miRNA ... - Nature.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Domcke, S. et al. Evaluating cell lines as tumour models by comparison of genomic profiles Continue reading →<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[27],"tags":[],"class_list":["post-1118600","post","type-post","status-publish","format-standard","hentry","category-human-genetics"],"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/1118600"}],"collection":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/comments?post=1118600"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/posts\/1118600\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/media?parent=1118600"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/categories?post=1118600"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/prometheism-transhumanism-posthumanism\/wp-json\/wp\/v2\/tags?post=1118600"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}